Quoin Pharmaceuticals Ltd. announced the dosing of the first patient in its open label clinical trial in Netherton Syndrome patients. The trial is a single arm, open label study, investigating the safety and efficacy of Quoin's lead candidate, QRX003, in Netherton Syndrome patients who are currently receiving off-label systemic therapy, primarily biologic therapy, and will continue to do so throughout the duration of the study. QRX003 will be applied once daily over a twelve-week period to pre-designated areas of the patient's body.

A number of different clinical endpoints are being assessed in the study, including an Investigator Global Assessment (IGA), a Patient Global Assessment (PaGA), as well as pruritus, among others. This study, which is Quoin's second study in Netherton patients, is running concurrently with the company's double blinded vehicle controlled study and is also being conducted under the company's open Investigational New Drug (IND). Quoin anticipates reporting topline data from this open-label study in the second half of 2023.